Serum Fstl1, a novel biomarker screened based on protein array technology, predict acute kidney injury and major renal adverse events after cardiac surgery: A prospective cohort study
Clinica Chimica Acta(2023)
Abstract
•Serum follistatin-like 1(Fstl1) can be used for early identification of cardiac surgery–associated AKI (CSA-AKI) and major renal adverse events.•Serum Fstl1 can be used as an important indicator for CSA-AKI model optimization.•Protein microarray technology can be used as a reliable method to detect CSA-AKI.
MoreTranslated text
Key words
Acute kidney injury,Cardiac surgery,Protein array technology,Follistatin-like 1,Prediction
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined